SS Innovations International Inc

SS Innovations International Inc(SSII)股票分析

$2.250

-0.114 (-5.06%)收盤時

Loading chart…
最高
2.395
開盤
2.330
成交量加權均價
2.28
成交量
41.02K
市值
—
最低
2.200
成交金額
93.59K
企業價值/稅息折舊攤銷前利潤(TTM)
-42.45

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

AI 分析 of SS Innovations International Inc (SSII)

賣出

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

估值指標

SS Innovations International Inc(SSII)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-15.35
目前EV/EBITDA
-42.45
高估
6.81
低估
-37.51

預期股價營收比

合理
5 年均值 P/S
3.23
目前P/S
6.34
高估
7.66
低估
-1.21

Alphio AI 對 SSII 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SSII

$8.47

情境價格

基

基準

基準 · 50%SSII

$7.13

情境價格

悲

悲觀

悲觀 · 25%SSII

$6.18

情境價格

事件時間軸

2026-10-13 (ET)

09:00:00

SS Innovations Submits Response to FDA Additional Information Request

2026-07-14 (ET)

09:00:00

SS Innovations Appoints Sarah Romano as CFO

2026-05-05 (ET)

09:00:00

SS Innovations Surpasses 10,500 Cumulative Surgeries

2026-05-01 (ET)

16:30:00

SS Innovations Files to Sell 5.02M Shares of Common Stock

16:30:00

SS Innovations Files $150M Mixed Securities Shelf

資訊

SSII 常見問題 —— 由 Alphio AI 解答

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易